The significance of defining preclinical or prodromal Parkinson's disease

被引:44
|
作者
Olanow, C. Warren [1 ,2 ]
Obeso, Jose A. [3 ]
机构
[1] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA
[3] Univ Navarra, Dept Neurol, E-31080 Pamplona, Spain
关键词
prodromal Parkinson's disease; Parkinson's disease; non-motor features; DELAYED-START TRIAL; DOUBLE-BLIND; RASAGILINE; DIAGNOSIS; THERAPIES; PATHOLOGY; FEATURES; NEED;
D O I
10.1002/mds.25019
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD. (C) 2012 Movement Disorder Society
引用
收藏
页码:666 / 669
页数:4
相关论文
共 50 条
  • [31] Diet to beat the odds of prodromal Parkinson's disease?
    Tangney, Christy C.
    [J]. MOVEMENT DISORDERS, 2019, 34 (01) : 2 - 3
  • [32] In vivo modeling of prodromal stage of Parkinson's disease
    Cerri, Silvia
    Blandini, Fabio
    [J]. JOURNAL OF NEUROSCIENCE METHODS, 2020, 342
  • [33] Symptoms and duration of the prodromal phase in Parkinson's disease
    Gonera, EG
    vantHof, M
    Berger, HJC
    vanWeel, C
    Horstink, WIM
    [J]. MOVEMENT DISORDERS, 1997, 12 (06) : 871 - 876
  • [34] Sleep changes as a prodromal marker of Parkinson's disease
    Iranzo, A.
    [J]. JOURNAL OF SLEEP RESEARCH, 2014, 23 : 53 - 53
  • [35] Cognitive complaint as a prodromal symptom in Parkinson's disease?
    Gerton, B. K.
    Tsuang, D. W.
    Peskind, E. R.
    Montine, T. J.
    Leverenz, J. B.
    [J]. MOVEMENT DISORDERS, 2009, 24 : S298 - S299
  • [36] Motor signs in the prodromal phase of Parkinson's disease
    Maetzler, Walter
    Hausdorff, Jeffrey M.
    [J]. MOVEMENT DISORDERS, 2012, 27 (05) : 627 - 633
  • [38] Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease
    Nakamura, Akinori
    Cuesta, Pablo
    Fernandez, Alberto
    Arahata, Yutaka
    Iwata, Kaori
    Kuratsubo, Izumi
    Bundo, Masahiko
    Hattori, Hideyuki
    Sakurai, Takashi
    Fukuda, Koji
    Washimi, Yukihiko
    Endo, Hidetoshi
    Takeda, Akinori
    Diers, Kersten
    Bajo, Ricardo
    Maestu, Fernando
    Ito, Kengo
    Kato, Takashi
    [J]. BRAIN, 2018, 141 : 1470 - 1485
  • [39] Hemifacial spasm as prodromal manifestation of Parkinson's disease
    Leonardos, A
    Potagas, C
    Vassilopoulos, D
    [J]. JOURNAL OF NEUROLOGY, 2005, 252 : 144 - 144
  • [40] Reply to: "Risk Disclosure in Prodromal Parkinson's Disease"
    Schaeffer, Eva
    Toedt, Inken
    Kohler, Susanne
    Rogge, Annette
    Berg, Daniela
    [J]. MOVEMENT DISORDERS, 2022, 37 (06) : 1327 - 1327